|
|||||
|
|
| erbB家族在肝细胞癌中的表达及临床意义 | |
| 引用本文： | 吴飞翔,赵荫农,曹骥,罗元,欧超,李瑗,苏建家. erbB家族在肝细胞癌中的表达及临床意义[J]. 中国肿瘤临床, 2004, 31(18): 1030-1032 |
| 作者姓名： | 吴飞翔 赵荫农 曹骥 罗元 欧超 李瑗 苏建家 |
| 作者单位： | 1. 广西医科大学附属肿瘤医院肝胆乳腺科,南宁市,520021 2. 广西医科大学附属肿瘤医院病理研究室,南宁市,520021 3. 广西医科大学附属肿瘤医院病理科,南宁市,520021 |
| 基金项目： | 广西留学回国人员科研项目 |
| 摘 要： | 目的:探讨erbB家族在肝细胞癌(HCC)组织中的表达及其意义.方法:采用免疫组化SP法检测55例HCC患者癌组织及癌旁组织中erbB家族中表皮生长因子受体(EGFR)、C-erbB-2、C-erbB-3、C-erbB-4的表达情况.结果:55例HCC患者癌组织及癌旁组织中,EGFR阳性表达率分别为58.18%(32/55)和36.36%(20/55),两者差异有显著性(P＜0.05);C-erbB-4阳性表达率分别为47.27%(26/55)和72.73%(40/55),两者差异有显著性(P＜0.05);而C-erbB-2、C-erbB-3在癌组织及癌旁组织中阳性表达率差异无显著性(P＞0.05).EGFR在HCC组织中的阳性表达率与临床分期、门静脉癌栓、肝外转移、术后复发等有关,C-erbB-2、C-erbB-3、C-erbB-4阳性表达率与各临床病理参数无关.结论:EGFR与肝癌的发生、发展有关,可作为HCC预后不良的参考指标;C-erbB-2及C-erbB-3可能与肝癌的发生、发展无关,而C-erbB-4低表达可能与HCC的发生有关. |
| 关 键 词： | 表皮生长因子受体 单克隆抗体 肝细胞癌 免疫组织化学 |
| 文章编号： | 1000-8179(2004)18-1030-03 |
| 修稿时间： | 2004-03-31 |
The Expression and Clinical Significance of erbB family in Hepatocellular Carcinoma |
|
| Wu Fei-xiang Zhao Yinnong Cao Ji et al. The Expression and Clinical Significance of erbB family in Hepatocellular Carcinoma[J]. Chinese Journal of Clinical Oncology, 2004, 31(18): 1030-1032 | |
| Authors: | Wu Fei-xiang Zhao Yinnong Cao Ji et al |
| Affiliation: | Wu Fei-xiang Zhao Yinnong Cao Ji et alDepartment of Hepatobiliary and Breast,the Affiliated Tumor Hospital of Guangxi Medical University,Nanning |
| Abstract: | Objective: In order to explore the expression and significance of the erbB family, the epidermal growth factor receptor (EGFR), C-erbB-2, C-erbB-3 and C-erbB-4 in human hepatocellular carcinoma(HCC) tissues. Methods: Immunohisto-chemistry was employed to determine the expression of erbB family in 55 cases of HCC and their adjacent liver tissues. Results: The positive rate of EGFR in the HCC tissues (58.18%, 32/55) was markedly higher than that in the adjacent liver tissues (36.36%, 20/55)(P<0.05). The positive rate of C-erbB-4, was significantly lower in the HCC tissues (47.27%, 26/55) than that of in the adjacent liver tissues (72.73%, 40/55) (P<0.05). However, no significant differences of positive rates of C-erbB-2 and C-erbB-3 in HCC tissues were observed (P>0.05) compared with their corresponding liver tissues, respectively. The expression of EGFR in the HCC tissues was significantly correlated with the clinical stage, the portal vein tumor thrombus, the presence of extrahepatic metastasis, and the recurrence of tumor; the expression of C-erbB-2? C-erbB-3 and C-erbB-4 were not correlated with the clinicopathological parameters. Conclusions: The results suggest that EGFR relates to the initiation and development of HCC. EGFR can be considered as predictive markers for treatment of HCC; C-erbB-2 and C-erbB-3 may not be involved in the initiation and progression of HCC, but the lower expression of c-erbB-4 may be relate to the initiation of HCC. |
| Keywords: | Epidermal growth factor receptor C-erbB-2 C-erbB-3 C-erbB-4 Hepatocellular carcinoma Immunohistochemistry |
| 本文献已被 CNKI 万方数据 等数据库收录！ | |